BOARD OF DIRECTORS
PRESENTATIONS
Helix BioMedix, Inc. (OTCBB: HXBM - News), a developer of bioactive peptides,today announced that its Annual Meeting of Stockholders will be held on Thursday, May 15, 2008, at 8:00 A.M. local time at the Washington Athletic Club, 1325 Sixth Avenue, Seattle, Washington 98101. Proxy materials were mailed on April 10, 2008 to all stockholders of record as of March 19, 2008.
The meeting will be broadcast live over the Internet and may be accessed by visiting the “Investors” section of the company’s website at www.helixbiomedix.com.
About Helix BioMedix, Inc.
Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically-applied products which offer the health, beauty and safety benefits of our advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptides.
Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take our product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, we are developing finished, peptide-based products to market with our partners.
More information about the company and its proprietary peptides may be found on the company’s website at www.helixbiomedix.com.
Forward Looking Statements
During the meeting management may make forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies,continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company’s reports and other filings with the Securities and Exchange Commission. Such filings are available on the company’s website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
Helix BioMedix Contacts:
Company Contact:
R. Stephen Beatty
President and CEO
425-402-8400
sbeatty@helixbiomedix.com
Investor Contact:
Ryan Bright
Shelton Group Investor Relations
972-239-5119 X 159
rbright@sheltongroup.com
